Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
삼성바이오에피스
이 회사 보도자료 구독
제약
인천
http://www.samsungbioepis.com
삼성바이오에피스 보도자료
14개
RSS
이메일
2020년 4월 16일
09:25
Samsung Bioepis Announces US Launch of ONTRUZANT® (trastuzumab-dttb) for Early and Metastatic HER2-overexpressing Breast Cancer and Metastatic Gastric Cancer
Samsung Bioepis Co., Ltd. announced today that ONTRUZANT® (trastuzumab-dttb), a biosimilar of the reference biologic medicine HERCEPTIN®[1] (trastuzumab) for the treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic
건강
제약
신상품
2019년 11월 7일
15:48
Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the Unit
건강
제약
제휴
2019년 10월 10일
10:48
Samsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
Samsung Bioepis Co., Ltd. today announced real-world data of BENEPALI™ in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The results will be presented at the
건강
제약
개발
2019년 9월 27일
11:13
Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress
Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients with metastatic or recurrent non-squamous non-small
건강
제약
조사연구
2016년 10월 4일
11:45
Samsung Bioepis' Marketing Authorization Application for SB3 Trastuzumab Biosimilar Candidate Accepted for Review by the European Medicines Agency
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB3, a biosimilar candidate referencing Herceptin® (trastuzumab). Herceptin® is a m
건강
제약
개발
2016년 9월 13일
11:25
Samsung Bioepis' SB4 (BRENZYS™) Becomes First Etanercept Biosimilar to Receive Regulatory Approval in Canada
Samsung Bioepis Co., Ltd. today announced that BRENZYS™ - a biosimilar referencing Enbrel® (etanercept), also known as SB4 - received regulatory approval in Canada for the treatment of rheumatoid arthritis and ankylosing spondylitis. BRENZYS™ will be
건강
제약
개발
2016년 7월 18일
11:15
Samsung Bioepis' Marketing Authorization Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the European Medicines Agency
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB5, a biosimilar candidate referencing Humira® (adalimumab). SB5 is Samsung Bio
건강
제약
개발
2016년 6월 9일
09:15
Samsung Bioepis Announces New Data on Three Anti-TNF-α Biosimilar Molecules at the Annual European Congress on Rheumatology (EULAR 2016)
Samsung Bioepis Co., Ltd. today announced new clinical data on its anti-TNF-α portfolio of Benepali® (etanercept), Flixabi® (infliximab) and SB5 (adalimumab) investigational biosimilar candidate. The data will be presented through seven poster presen
건강
제약
개발
2016년 5월 30일
13:55
Samsung Bioepis Becomes First to Obtain European Commission Approval for Second Anti-TNF-α Biosimilar with Flixabi®
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Flixabi® - a biosimilar version of Remicade® (infliximab), also known as SB2 - for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylo
건강
제약
개발
2016년 5월 24일
10:10
Samsung Bioepis' Biologics License Application for SB2 Infliximab Biosimilar Accepted by U.S. Food and Drug Administration
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for SB2, a biosimilar candidate referencing Remicade® (infliximab), for the treatment
건강
제약
개발
2016년 4월 4일
09:00
Samsung Bioepis' Flixabi® Infliximab Biosimilar Recommended for Approval in the European Union
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Flixabi® - a biosimilar version of Remicade® (infliximab), also known as SB2
건강
제약
개발
2016년 1월 18일
09:20
Samsung Bioepis Enters the European Biopharmaceutical Market with Benepali®, the First Fusion Protein Biosimilar Approved by the European Commission
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Benepali® - a biosimilar referencing Enbrel® (etanercept), also known as SB4 - for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthriti
건강
제약
개발
2015년 12월 7일
09:30
Samsung Bioepis' RENFLEXIS® Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® - a biosimilar version of Remicade® (infliximab), also known as SB2 - for the treatment of rheumatoid arthritis, ankylosing spondyl
건강
제약
개발
2015년 11월 23일
10:15
Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union
Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Benepali® - a biosimilar version of Enbrel® (etanercept), previously known as
건강
제약
개발
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기